Management Presentation

Sandoz at a glance USD 208bn Market size1 USD 9.1bn FY 2022 net sales3,4 A European champion Growing at 8% 1,2 with increasing share of Biosimilars Strong pipeline USD 1.9bn FY 2022 core EBITDA4 100+ markets served >400 Generics 25 Biosimilars Broad coverage across Europe, North America and International And the global leader in Generics and Biosimilars Strong management team Supported by >22,000 employees 5 3 1. Based on Company analysis using IQVIA Analytics Link MAT12-2022 data in LCUSD at gross price, excludes certain sizeable markets with no or limited Sandoz operations; 2. 2022-2031 CAGR for Biocomparable, Early Entry Generics and Generics as defined by IQVIA and includes all ATC and NFC forms; 3. Net sales to third parties; 4. Based on carve-out financials. For additional information regarding the core results, which are non-IFRS measures, including a reconciliation to the most directly comparable measures presented in accordance with IFRS, see "Appendix" starting on slide 31; 5. Approximate number of FTEs at spin-off. Management Presentation SANDOZ

View entire presentation